Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8744738 | 0.98 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| Hydrochloric Acid SCHEMBL1533600 | 0.96 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| SCHEMBL883159 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| Hydrochloric Acid SCHEMBL690938 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| Bromide SCHEMBL19378722 | 0.87 | MAPT (0.61) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| SCHEMBL10337516 | 0.84 | MAPT (0.64) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| SCHEMBL45515 | 0.84 | MAPT (0.64) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| SCHEMBL9683457 | 0.83 | MAPK13 (0.55) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| Hydrochloric Acid SCHEMBL194804 | 0.82 | MAPT (0.61) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B | |
| Water SCHEMBL18694848 | 0.82 | MAPT (0.61) | SMN1; SMN2MAPTL3MBTL1PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | SMN1; SMN2 4750/4885MAPT 4151/4885L3MBTL1 3205/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | SMN1; SMN2 4750/4885MAPT 4151/4885L3MBTL1 3205/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | SMN1; SMN2 4750/4885MAPT 4151/4885L3MBTL1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.